Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California cancer consortium study

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 723-728

  Morgan Jr , Robert J ^a   Leong, Lucille ^a   Chow, Warren ^a   Gandara, David ^b   Frankel, Paul ^a   Garcia, Agustin ^c   Lenz, Heinz Josef ^c   Doroshow, James H ^a,d  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bryostatin; Chemomodulation; Chemotherapy; Cisplatin; Phase II

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BRYOSTATIN 1; CISPLATIN; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; BRYOSTATIN; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SEIZURE; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE; UNITED STATES; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; ENZYMOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRYOSTATINS; CALIFORNIA; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862295855     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9557-5     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249
2. Cannistra SA, Gershenson D, Recht A (2008) Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT Jr, Lawrence TS, Rosenberg S (eds) Cancer: principles and practice of oncology. Lippincott Williams & Wilkins, Philadelphia, pp 1568-1594
3. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 (26):1950-1955
4. Sabbatini P, Spriggs D (1998) Salvage therapy for ovarian cancer. Oncology 12(6):833-848
5. Stanwell C, Gescher A, Bradshaw TD, Pettit GR (1994) The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Int J Cancer 56:585-592
6. Hornung RL, Pearson JW, Beckwith M, Longo DL (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52:101-107
7. Dale IL, Bradshaw TD, Gescher A, Pettit GR (1989) Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. Cancer Res 49:3242-3245
8. Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR, Grant S (1994) Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 47:839-852
9. Asiedu C, Biggs J, Lilly M, Kraft AS (1995) Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res 55:3716-3720
10. Basu A, Lazo JS (1992) Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. Cancer Res 52:3119-3124
11. Hofmann J, Doppler W, Jakob A, Maly K, Posch L, Uberall F, Grunicke HH (1988) Enhancement of the antiproliferative effect of cis- diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 42:382-388
12. Isonishi S, Andrews PA, Howell SB (1990) Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem 265:3623-3627
13. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
14. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
15. Green S, Weiss G (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253
16. Stanwell C (1994) The role of protein kinase C (PKC) modulation in the antiproliferative effects of bistratene A, bryostatin 1 and phorbol esters. Diss Abstr Int [C] 55:881
17. Dale IL, Gescher A (1989) Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer 43:158-163
18. Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR, Hess AD (1991) Successful treatment of murine melanoma with bryostatin 1. Cancer Res 51:682-687
19. Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD, Al-Katib AM (1998) Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16:56-62
20. Basu A, Teicher BA, Lazo JS (1990) Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis- diamminedichloroplatinum(II). J Biol Chem 265:8451-8457
21. Martiny-Baron G, Fabbro D (2007) Classical PKC isoforms in cancer. Pharmacol Res 55:477-486
22. Serova M, Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E (2006) Preclinical and clinical development of novel agents that target the protein kinase C Family. Sem Oncol 33:466-478
23. Hanauske A-R, Sundell K, Lahn M (2004) The role of protein kinases C-alpha (PKC-α) in cancer and its modulation by the novel PKC-α-specific inhibitor aprinocarsen. Curr Pharm Des 10 (16):1923-1936
24. Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, Liebes L, Muggia F (2009) Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemother Pharmacol 64:803-810
25. Hickman PF, Kemp GJ, Thompson CH, Salisbury AJ, Wade K, Harris AL, Radda GK (1995) Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br J Cancer 72:998-1003
26. Thompson CH, Macaulay VM, O'Byrne KJ, Kemp GJ, Wilner SM, Talbot DC, Harris AL, Radda GK (1996) Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. Br J Cancer 73:1161-1165
27. Lenz HJ, Raghavan D, Doroshow J, Gandara DR (1999) Phase I study of bryostatin-1 in combination with cisplatin in treating patients with metastatic or unresectable solid tumors including non small-cell lung cancer. Clin Lung Cancer 1 (2):151-152